APOBEC mutational activity appears to be prognostic in patients with newly diagnosed multiple myeloma or precursor diseases who receive daratumumab quadruplets, according to Kylee Maclachlan, MBChB, PhD.
Findings from the phase 3 SWOG S1011 trial highlight no significant differences between extended lymphadenectomy vs standard lymphadenectomy in terms of disease-free survival in patients with muscle-invasive breast cancer.
Circulating tumor DNA (ctDNA)-based next- generation sequencing (NGS) assays have advantages over classic tissue-based analyses because of their low invasiveness and availability of repeated sampling. The existence of various companion trials for common alterations that can be potential therapy targets on the
2 platforms can lead to future international collaboration.
A Satellite Sessions program panel at the University of Texas MD Anderson Cancer Center discusses topics in multiple myeloma including the selection of triplet vs quadruplet treatment regimens and optimizing outcomes in the maintenance setting.
The emergence of using hypofractionated radiation treatments—fewer radiation treatments at larger doses—across cancer types may place financial strain on radiation oncologists, but one expert notes there’s still continued success.